Cutera, Inc. (NASDAQ:CUTR) EVP Larry Laber sold 5,843 shares of the stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $45.35, for a total transaction of $264,980.05. Following the completion of the transaction, the executive vice president now owns 79,463 shares of the company’s stock, valued at approximately $3,603,647.05. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Larry Laber also recently made the following trade(s):

  • On Wednesday, November 15th, Larry Laber sold 1,250 shares of Cutera stock. The shares were sold at an average price of $44.30, for a total transaction of $55,375.00.
  • On Wednesday, November 8th, Larry Laber sold 1,700 shares of Cutera stock. The shares were sold at an average price of $42.15, for a total transaction of $71,655.00.
  • On Monday, November 6th, Larry Laber sold 500 shares of Cutera stock. The shares were sold at an average price of $41.50, for a total transaction of $20,750.00.
  • On Monday, October 16th, Larry Laber sold 500 shares of Cutera stock. The shares were sold at an average price of $40.50, for a total transaction of $20,250.00.

Cutera, Inc. (NASDAQ:CUTR) traded down $1.10 on Thursday, hitting $44.25. 222,724 shares of the company traded hands, compared to its average volume of 222,400. Cutera, Inc. has a twelve month low of $17.48 and a twelve month high of $48.95. The firm has a market capitalization of $620.42, a PE ratio of 59.00, a PEG ratio of 1.35 and a beta of 0.52.

Cutera (NASDAQ:CUTR) last posted its quarterly earnings results on Tuesday, November 7th. The medical device company reported $0.42 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.08 by $0.34. Cutera had a net margin of 7.99% and a return on equity of 18.73%. The firm had revenue of $38.17 million for the quarter, compared to analyst estimates of $34.82 million. During the same quarter last year, the firm posted $0.12 earnings per share. Cutera’s revenue for the quarter was up 26.1% compared to the same quarter last year. sell-side analysts anticipate that Cutera, Inc. will post 0.55 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of CUTR. Bank of New York Mellon Corp raised its stake in shares of Cutera by 47.1% during the second quarter. Bank of New York Mellon Corp now owns 149,644 shares of the medical device company’s stock valued at $3,876,000 after purchasing an additional 47,926 shares during the period. Federated Investors Inc. PA raised its stake in shares of Cutera by 2.5% during the second quarter. Federated Investors Inc. PA now owns 58,415 shares of the medical device company’s stock valued at $1,513,000 after purchasing an additional 1,427 shares during the period. Kennedy Capital Management Inc. purchased a new stake in shares of Cutera during the second quarter valued at approximately $9,426,000. Wells Fargo & Company MN grew its position in shares of Cutera by 116.3% during the second quarter. Wells Fargo & Company MN now owns 42,960 shares of the medical device company’s stock worth $1,112,000 after buying an additional 23,097 shares in the last quarter. Finally, Alliancebernstein L.P. acquired a new stake in shares of Cutera during the second quarter worth approximately $848,000. Hedge funds and other institutional investors own 87.64% of the company’s stock.

CUTR has been the topic of a number of research reports. Roth Capital increased their price objective on shares of Cutera from $41.00 to $47.00 and gave the company a “buy” rating in a research note on Tuesday, September 12th. Maxim Group cut shares of Cutera from a “buy” rating to a “hold” rating in a research note on Thursday, September 14th. Zacks Investment Research cut shares of Cutera from a “buy” rating to a “hold” rating in a research note on Tuesday, October 10th. Finally, BidaskClub raised shares of Cutera from a “hold” rating to a “buy” rating in a research note on Tuesday, December 12th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $37.33.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright laws. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/04/larry-laber-sells-5843-shares-of-cutera-inc-cutr-stock.html.

About Cutera

Cutera, Inc is a medical device company. The Company is engaged in the design, development, manufacture, marketing and servicing of laser and other energy-based aesthetics systems for practitioners across the world. The Company offers products based on product platforms, such as enlighten, excel HR, truSculpt, excel V and xeo, each of which enables physicians and other practitioners to perform aesthetic procedures for customers.

Insider Buying and Selling by Quarter for Cutera (NASDAQ:CUTR)

Receive News & Ratings for Cutera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera and related companies with MarketBeat.com's FREE daily email newsletter.